2022
Holistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook
Jaffe A, Taddei TH, Giannini EG, Ilagan‐Ying Y, Colombo M, Strazzabosco M. Holistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook. Liver International 2022, 42: 2607-2619. PMID: 36161463, PMCID: PMC10878125, DOI: 10.1111/liv.15432.Peer-Reviewed Original ResearchConceptsLiver diseaseHepatocellular carcinomaLiver functionRisk factorsRelevant prognostic roleChronic hepatitis BResidual liver functionChronic liver diseaseManagement of patientsCare of patientsCommon risk factorsAppropriate surveillance strategiesSuccessful cancer treatmentC infectionCommon complicationHepatitis BMetabolic syndromePrognostic roleSignificant morbidityLongitudinal careCurrent careCancer recurrenceHCC managementLiver cancerHCC treatmentInflammatory pathways and cholangiocarcioma risk mechanisms and prevention
Cadamuro M, Strazzabosco M. Inflammatory pathways and cholangiocarcioma risk mechanisms and prevention. Advances In Cancer Research 2022, 156: 39-73. PMID: 35961707, PMCID: PMC10916841, DOI: 10.1016/bs.acr.2022.02.001.Peer-Reviewed Original ResearchMeSH KeywordsBile Duct NeoplasmsBile Ducts, IntrahepaticCholangiocarcinomaCholangitis, SclerosingHumansRisk FactorsConceptsDevelopment of cholangiocarcinomaNonalcoholic fatty liver diseaseAdequate therapeutic treatmentPrimary sclerosing cholangitisFatty liver diseasePro-inflammatory mechanismsMain risk factorsProdromal diseaseSclerosing cholangitisCaroli's diseaseMetabolic syndromeChronic cholangiopathiesLiver diseasePoor prognosisInflammatory pathwaysBiliary treeCCA developmentRisk factorsImmune responseImmunological responseTherapeutic targetCholangiocarcinomaFluke infestationRole of cellExtrahepatic areas
2017
Direct‐acting antivirals combination for elderly patients with chronic hepatitis C: A cost‐effectiveness analysis
Ciaccio A, Cortesi PA, Bellelli G, Rota M, Conti S, Okolicsanyi S, Rota M, Cesana G, Mantovani LG, Annoni G, Strazzabosco M. Direct‐acting antivirals combination for elderly patients with chronic hepatitis C: A cost‐effectiveness analysis. Liver International 2017, 37: 982-994. PMID: 27943549, DOI: 10.1111/liv.13339.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overAntiviral AgentsComputer SimulationCost-Benefit AnalysisDecision Support TechniquesDisease ProgressionDrug CostsDrug Therapy, CombinationFemaleFrail ElderlyGeriatric AssessmentHepatitis C, ChronicHumansLiver CirrhosisMaleMarkov ChainsModels, EconomicQuality-Adjusted Life YearsRisk FactorsTime FactorsTreatment OutcomeConceptsIncremental cost-effectiveness ratioChronic hepatitis CQuality-adjusted life yearsCost-effectiveness ratioElderly patientsCHC patientsHepatitis CFrailty phenotypeFrailty statusFibrosis stageLife yearsElderly CHC patientsMild fibrosis stageInterferon-free treatmentHealthcare system perspectiveLifetime time horizonCost-effectiveness analysisDAA treatmentDAA combinationsAdvanced fibrosisFrail subjectsClinical variablesLiver fibrosisF2 patientsAge 75
2015
Recipient female gender is a risk factor for graft loss after liver transplantation for chronic hepatitis C: Evidence from the prospective Liver Match cohort
Belli LS, Romagnoli R, Nardi A, Marianelli T, Donato F, Corradini SG, Iemmolo RM, Morelli C, Pasulo L, Rendina M, De Martin E, Ponziani FR, Volpes R, Strazzabosco M, Angelico M, Investigators L. Recipient female gender is a risk factor for graft loss after liver transplantation for chronic hepatitis C: Evidence from the prospective Liver Match cohort. Digestive And Liver Disease 2015, 47: 689-694. PMID: 26055490, DOI: 10.1016/j.dld.2015.04.006.Peer-Reviewed Original ResearchConceptsRecipient female genderGraft lossFemale genderLiver transplantationRisk factorsEnd-stage liver disease (MELD) scoreFive-year graft survivalStage liver disease scoreOutcome of HCVSevere HCV recurrenceChronic hepatitis CHCV-positive patientsLiver Disease scoreHepatitis C virusHCV recurrenceGraft outcomeGraft survivalHepatitis CPortal thrombosisTransplant recipientsLiver graftsIndependent determinantsRetrospective studyC virusMatch cohort
2014
A Bayesian methodology to improve prediction of early graft loss after liver transplantation derived from the Liver Match study
Angelico M, Nardi A, Romagnoli R, Marianelli T, Corradini SG, Tandoi F, Gavrila C, Salizzoni M, Pinna AD, Cillo U, Gridelli B, De Carlis LG, Colledan M, Gerunda GE, Costa AN, Strazzabosco M, Investigators L, Committee: L, Angelico M, Cillo U, Fagiuoli S, Strazzabosco M, Board: A, Caraceni P, Toniutto P, Board: C, Costa A, Investigators: P, Salizzoni T, Romagnoli R, Bertolotti G, Patrono D, De Carlis L, Slim A, Mangoni J, Rossi G, Caccamo L, Antonelli B, Mazzaferro V, Regalia E, Sposito C, Colledan M, Corno V, Tagliabue F, Marin S, Cillo U, Vitale A, Gringeri E, Donataccio M, Donataccio D, Baccarani U, Lorenzin D, Bitetto D, Valente U, Gelli M, Cupo P, Gerunda G, Rompianesi G, Pinna A, Grazi G, Cucchetti A, Zanfi C, Risaliti A, Faraci M, Tisone G, Anselmo A, Lenci I, Sforza D, Agnes S, Di Mugno M, Avolio A, Ettorre G, Miglioresi L, Vennarecci G, Berloco P, Rossi M, Corradini S, Molinaro A, Calise F, Scuderi V, Cuomo O, Migliaccio C, Lupo L, Notarnicola G, Gridelli B, Volpes R, Petri S, Zamboni F, Carbotta G, Dedola S, Collection and Verification and Biostatistics: D, Nardi A, Marianelli T, Gavrila C, Ricci A, Vespasiano F. A Bayesian methodology to improve prediction of early graft loss after liver transplantation derived from the Liver Match study. Digestive And Liver Disease 2014, 46: 340-347. PMID: 24411484, DOI: 10.1016/j.dld.2013.11.004.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedBayes TheoremBody Mass IndexCohort StudiesCold IschemiaDelayed Graft FunctionEnd Stage Liver DiseaseFemaleGraft RejectionGraft SurvivalHumansItalyLiver TransplantationMaleMiddle AgedMultivariate AnalysisPrimary Graft DysfunctionProportional Hazards ModelsProspective StudiesRisk AssessmentRisk FactorsTissue DonorsTreatment OutcomeConceptsEarly graft lossGraft lossUnited NetworkLiver transplantationPrior upper abdominal surgeryDonor body mass indexProspective European cohortsUpper abdominal surgeryOrgan Sharing registryPrimary liver transplantCold ischaemia timeBody mass indexRisk indexRecipient creatinineBayesian Cox modelsLiver transplantPortal thrombosisAbdominal surgeryCardiac deathIschaemia timeMass indexDonor ageEuropean cohortOrgan SharingCox model
2008
Incidence and Management of Colorectal Cancer in Liver Transplant Recipients
Nishihori T, Strazzabosco M, Saif MW. Incidence and Management of Colorectal Cancer in Liver Transplant Recipients. Clinical Colorectal Cancer 2008, 7: 260-266. PMID: 18650194, PMCID: PMC3755274, DOI: 10.3816/ccc.2008.n.033.Peer-Reviewed Original ResearchConceptsLiver transplant recipientsTransplant recipientsColorectal cancerLiver transplantationPatient populationColon cancerDe novo colorectal cancerDe novo malignanciesLong-term immunosuppressionMetastatic colorectal cancerPrimary sclerosing cholangitisInflammatory bowel diseaseMajor health concernChronic rejectionNovo malignanciesProlonged immunosuppressionSclerosing cholangitisPosttransplantation periodBiologic agentsBowel diseaseCombination chemotherapyProphylactic colectomyOverall incidenceCommon malignancyLymphoproliferative diseasePrognostic Prediction in Hepatocellular Carcinoma
Strazzabosco M, Cohen E, Emre S. Prognostic Prediction in Hepatocellular Carcinoma. Journal Of Clinical Gastroenterology 2008, 42: 221-223. PMID: 18223506, DOI: 10.1097/mcg.0b013e31815ed0a9.Peer-Reviewed Original Research